Recently, a study that evaluated the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in stage II TRD patients showed a mean remission rate of 37.3% [21] and these results are in line with those of our study. The gene discussed is TG; the disease is treatment resistant depression.